Patents by Inventor Gregor Anderluh

Gregor Anderluh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PORE MONOMERS AND PORES
    Publication number: 20260285921
    Abstract: The present invention relates to novel actinoporin monomers, actinoporin pores formed from the monomers and their uses in analyte detection and characterisation.
    Type: Application
    Filed: April 15, 2024
    Publication date: September 24, 2026
    Applicants: Oxford Nanopore Technologies PLC, National Institute of Chemistry
    Inventors: Elizabeth Jayne Wallace, Michael Robert Jordan, Lakmal Nishantha Jayasinghe, Tomaz Svigelj, Marija Srnko, Gasper Solinc, Ana Crnkovic, Marjetka Podobnik, Gregor Anderluh
  • Fusion proteins
    Patent number: 7348408
    Abstract: The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or purification systems. The present inventors have found that the TolAIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell. In one aspect of the invention, a TolAIII domain or a functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and a non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: March 25, 2008
    Assignee: Newcastle University Ventures Limited
    Inventors: Isa Gokce, Gregor Anderluh, Jeremy Hugh Lakey
  • Fusion proteins
    Publication number: 20050130269
    Abstract: The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or purification systems. The present inventors have found that the TolAIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell. In one aspect of the invention, a TolAIII domain or a functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and a non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide.
    Type: Application
    Filed: January 10, 2003
    Publication date: June 16, 2005
    Inventors: Isa Gokce, Gregor Anderluh, Jeremy Lakey